NextBioMedical Co

NextBioMedical Co Interest Expense

The Interest Expense of NextBioMedical Co (389650.KQ) as of Oct 23, 2026 is 1.36 B KRW. In the previous year, Interest Expense was 134.07 M KRW — a change of 911.52% (higher).

Interest Expense

1.36 BKRW

YoY

911.52%

Last updated:

Interest Expense of NextBioMedical Co is 2024 1.36 B KRW. Interest Expense of NextBioMedical Co was 2023 134.07 M KRW. It decreases by 911.52% higher compared to the previous year.

The NextBioMedical Co Interest Expense history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Interest Expense
Date
Interest Expense
Jan 1, 2022
-198.86 M KRW
Jan 1, 2023
134.07 M KRW
Jan 1, 2024
1.36 B KRW
The NextBioMedical Co Interest Expense history
YEARInterest ExpenseYoY
1.36 BKRW+911.52%
134.07 MKRW-167.42%
-198.86 MKRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

NextBioMedical Co Stock analysis

What does NextBioMedical Co do? NextBioMedical Co Ltd generates revenue through the manufacturing and sales of medical equipment, including endoscopic hemostatic agents and vascular embolic microspheres. The company focuses on research and development within the health care equipment and supplies sector, targeting healthcare providers and medical institutions that require specialized equipment for procedures such as endoscopy and vascular interventions. Its products are designed to address specific clinical needs, supporting both diagnostic and therapeutic applications in medical settings. The company operates in the Health Care Equipment & Supplies industry, with a primary focus on Korea-based manufacturing and sales. Its product portfolio includes endoscopic hemostatic agents, which are used to control bleeding during endoscopic procedures, and vascular embolic microspheres, utilized in embolization treatments for vascular conditions. These products are sold to hospitals and medical facilities that require advanced medical solutions for patient care. NextBioMedical Co Ltd's business model relies on the consistent demand for specialized medical equipment in the healthcare sector. By developing and commercializing products such as endoscopic hemostatic agents and vascular embolic microspheres, the company serves healthcare providers seeking reliable and innovative tools for minimally invasive procedures. The company's research and development efforts aim to enhance product efficacy and expand its market presence within the medical equipment industry. NextBioMedical Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about NextBioMedical Co stock

Interest Expense of NextBioMedical Co is 1.36 B KRW in 2024.

Interest Expense of NextBioMedical Co changed from 134.07 M KRW to 1.36 B KRW, representing a 911.52% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Interest Expense NextBioMedical Co since 2006 – with annual values, charts, and detailed analysis.

Interest expense represents the cost of borrowing. Higher interest expenses can indicate a highly leveraged company.

Interest Expense's KRW is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Interest Expense's NextBioMedical Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — NextBioMedical Co

All Key Metrics — NextBioMedical Co